|
|
Post by lakers on Jan 5, 2016 12:53:17 GMT -5
This photo provided by Sanofi-Aventis shows an Afrezza inhaler with cartridges of inhalation powder. As a result of a squashed licensing deal between Mannkind and Sanofi, Mannkind said it is reviewing its strategic options for Afrezza. Photo: Associated Press By Lisa Beilfuss Updated Jan. 5, 2016 11:48 a.m. ET MannKind Corp. on Tuesday announced the termination of its licensing pact with Sanofi-Aventis in the U.S. for the development and sale of its inhaled insulin product Afrezza and signaled that it might look to sell the drug. Shares of the company tumbled 27% in midday trading. Over the past three months, shares have dropped 67%, including Tuesday’s decline. MannKind said that it and Sanofi would begin transition talks to return Afrezza to MannKind over the next three to six months, with the termination effective no later than July 4. As a result of the squashed deal, MannKind said it is reviewing its strategic options for Afrezza. The evaluation of options typically include a full or partial sale. The company struck the marketing deal with French drug company Sanofi in August 2014. In its most recent quarterly earnings call with analysts and investors, then-Chief Executive Hakan Edstrom said MannKind was “disappointed with the growth of Afrezza sales during the first nine months of the year,” pointing to insurance reimbursement issues and slow uptake. Mr. Edstrom stepped down as CEO in November. The abandoned partnership is the latest flop for inhaled insulins. In 2007, Pfizer Inc. pulled its product Exubera due to disappointing sales, partially the result of concerns among doctors about its long-term safety, costing the company about $2.8 billion. Sanofi was involved with the rollout of Exubera. The disappointing performance of inhaled insulins underpins the challenges pharmaceutical makers face in trying to replace chemical-based medicines whose patent protections are expiring. In the case of inhaled insulin, the endeavor is costly as inhalers use much more insulin than syringes since less of the drug makes it into the bloodstream. At the same time, doctors have expressed concerns over the impact inhaled insulin has on a patient’s lungs. www.wsj.com/articles/mannkind-sanofi-end-licensing-pact-for-diabetes-medicine-afrezza-1452008402 |
|
|
|
Post by lakers on Jan 5, 2016 13:02:41 GMT -5
I'd imagine both TEVA and GSK want Mnkd's TS. I refrain from saying the not obvious ... Hakan said Mnkd at its core is a drug dev co. As such, Afrezza may potentially be spun off. The remaining co will focus on drug dev alone, not mfgr. With upcoming partnerships, BoD may potentially consider spinning off to increase SH value. Read more: mnkd.proboards.com/thread/4643/mannkind-approach-gsk-ts-migraine#ixzz3wOVO3Yjr |
|
|
|
Post by bradleysbest on Jan 5, 2016 13:51:17 GMT -5
Someone has to want it...... Sell it to a SNY competitor!
|
|
|
|
Post by gwb on Jan 5, 2016 13:53:46 GMT -5
I'd imagine both TEVA and GSK want Mnkd's TS. I refrain from saying the not obvious ... Hakan said Mnkd at its core is a drug dev co. As such, Afrezza may potentially be spun off. The remaining co will focus on drug dev alone, not mfgr. With upcoming partnerships, BoD may potentially consider spinning off to increase SH value. Read more: mnkd.proboards.com/thread/4643/mannkind-approach-gsk-ts-migraine#ixzz3wOVO3YjrLakers you post on Dec 21, 2015 the following ;1. Sanofi partnership remains STRONG, going full tilt in 1Q16. I unequivocally believe the death of the partnership has been greatly exaggerated. You can stop doubting it now. For non-believers, you can write off for tax now if it makes you sleep better. But if you are still in, absolutely don't lose sleep over it.
Read more: mnkd.proboards.com/user/1882/recent#ixzz3wOgtXdgc
Lakers what changed ? Was Al asking crazy dollars for Afrezza ? SNY couldn't have just realized that Afrezza sales suck , they have sucked all year . It appears all of us are in shock over this sudden change of direction . What could have possibility changed ?
|
|
|
|
Post by mnkdnewbie on Jan 5, 2016 14:09:38 GMT -5
I'd imagine both TEVA and GSK want Mnkd's TS. I refrain from saying the not obvious ... Hakan said Mnkd at its core is a drug dev co. As such, Afrezza may potentially be spun off. The remaining co will focus on drug dev alone, not mfgr. With upcoming partnerships, BoD may potentially consider spinning off to increase SH value. Read more: mnkd.proboards.com/thread/4643/mannkind-approach-gsk-ts-migraine#ixzz3wOVO3YjrLakers you post on Dec 21, 2015 the following ;1. Sanofi partnership remains STRONG, going full tilt in 1Q16. I unequivocally believe the death of the partnership has been greatly exaggerated. You can stop doubting it now. For non-believers, you can write off for tax now if it makes you sleep better. But if you are still in, absolutely don't lose sleep over it.
Read more: mnkd.proboards.com/user/1882/recent#ixzz3wOgtXdgc
Lakers what changed ? Was Al asking crazy dollars for Afrezza ? SNY couldn't have just realized that Afrezza sales suck , they have sucked all year . It appears all of us are in shock over this sudden change of direction . What could have possibility changed ?
What happens if MNKD got an offer and Sanofi had the right to beat that offer, Sanofi passed and MNKD accepted the offer relieved Hakan and brought on the new CEO knowing they were terminating on Jan 5th because they accepted the other offer? Could that be possible and it will be announced at CC today? That was in the partnership that Sanofi had first dibs but they passed.... |
|
|
|
Post by jpg on Jan 5, 2016 14:13:19 GMT -5
Lakers you post on Dec 21, 2015 the following ;1. Sanofi partnership remains STRONG, going full tilt in 1Q16. I unequivocally believe the death of the partnership has been greatly exaggerated. You can stop doubting it now. For non-believers, you can write off for tax now if it makes you sleep better. But if you are still in, absolutely don't lose sleep over it.
Read more: mnkd.proboards.com/user/1882/recent#ixzz3wOgtXdgc
Lakers what changed ? Was Al asking crazy dollars for Afrezza ? SNY couldn't have just realized that Afrezza sales suck , they have sucked all year . It appears all of us are in shock over this sudden change of direction . What could have possibility changed ?
What happens if MNKD got an offer and Sanofi had the right to beat that offer, Sanofi passed and MNKD accepted the offer relieved Hakan and brought on the new CEO knowing they were terminating on Jan 5th because they accepted the other offer? Could that be possible and it will be announced at CC today? That was in the partnership that Sanofi had first dibs but they passed.... No... |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 14:19:01 GMT -5
Lakers you post on Dec 21, 2015 the following ;1. Sanofi partnership remains STRONG, going full tilt in 1Q16. I unequivocally believe the death of the partnership has been greatly exaggerated. You can stop doubting it now. For non-believers, you can write off for tax now if it makes you sleep better. But if you are still in, absolutely don't lose sleep over it.
Read more: mnkd.proboards.com/user/1882/recent#ixzz3wOgtXdgc
Lakers what changed ? Was Al asking crazy dollars for Afrezza ? SNY couldn't have just realized that Afrezza sales suck , they have sucked all year . It appears all of us are in shock over this sudden change of direction . What could have possibility changed ?
What happens if MNKD got an offer and Sanofi had the right to beat that offer, Sanofi passed and MNKD accepted the offer relieved Hakan and brought on the new CEO knowing they were terminating on Jan 5th because they accepted the other offer? Could that be possible and it will be announced at CC today? That was in the partnership that Sanofi had first dibs but they passed.... google "material information" as it relates to public companies. Read about the requirements involving communicating material information. MNKD can't sit on info. Private companies can pretty much do as they please but not public companies. If an actual offer was made mnkd would be legally required to divulge the offer regardless of whether they accept or reject it. It's material information. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 14:18:59 GMT -5
Lakers you post on Dec 21, 2015 the following ;1. Sanofi partnership remains STRONG, going full tilt in 1Q16. I unequivocally believe the death of the partnership has been greatly exaggerated. You can stop doubting it now. For non-believers, you can write off for tax now if it makes you sleep better. But if you are still in, absolutely don't lose sleep over it.
Read more: mnkd.proboards.com/user/1882/recent#ixzz3wOgtXdgc
Lakers what changed ? Was Al asking crazy dollars for Afrezza ? SNY couldn't have just realized that Afrezza sales suck , they have sucked all year . It appears all of us are in shock over this sudden change of direction . What could have possibility changed ?
What happens if MNKD got an offer and Sanofi had the right to beat that offer, Sanofi passed and MNKD accepted the offer relieved Hakan and brought on the new CEO knowing they were terminating on Jan 5th because they accepted the other offer? Could that be possible and it will be announced at CC today? That was in the partnership that Sanofi had first dibs but they passed.... cos if it so.. the termination news release would be different. No point in putting the dates/comments for nothing and to fool whom? |
|
